GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. announced today that it has filed a patent application with the US Patent and Trade Office (USPTO) for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors. “There is an important need to identify new targets for developing diagnostic tools and novel therapies for life-threatening illnesses, especially pancreatic cancer where very few treatment options exist. Furthermore, developing a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease,” said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.
